Company Analysis Fennec Pharmaceuticals Inc.
1. Summary
Advantages
- Price (6.75 $) is less than fair price (8.95 $)
- The company's current efficiency (ROE=141.31%) is higher than the sector average (ROE=9.78%)
Disadvantages
- Dividends (0%) are below the sector average (0.5351%).
- The stock's return over the last year (-28.51%) is lower than the sector average (-21.54%).
- Current debt level 115.81% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Fennec Pharmaceuticals Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5.6% | -20.4% | -3.3% |
| 90 days | 15.8% | -22.2% | -3.3% |
| 1 year | -28.5% | -21.5% | 17.1% |
FENC vs Sector: Fennec Pharmaceuticals Inc. has significantly underperformed the "Healthcare" sector by -6.98% over the past year.
FENC vs Market: Fennec Pharmaceuticals Inc. has significantly underperformed the market by -45.59% over the past year.
Stable price: FENC is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: FENC with weekly volatility of -0.5483% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (6.75 $) is lower than the fair price (8.95 $).
Price significantly below the fair price: The current price (6.75 $) is 32.6% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.27).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.14).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-25.19) is lower than that of the sector as a whole (4.64).
P/BV vs Market: The company's P/BV (-25.19) is lower than that of the market as a whole (3.44).
4.4. P/S
P/S vs Sector: The company's P/S indicator (13.46) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (13.46) is higher than that of the market as a whole (10.29).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-23.65) is lower than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (-23.65) is lower than that of the market as a whole (25.46).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -1.74% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-1.74%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (106.41%).
5.4. ROE
ROE vs Sector: The company's ROE (141.31%) is higher than that of the sector as a whole (9.78%).
ROE vs Market: The company's ROE (141.31%) is higher than that of the market as a whole (8.96%).
5.5. ROA
ROA vs Sector: The company's ROA (-61.13%) is lower than that of the sector as a whole (0.33%).
ROA vs Market: The company's ROA (-61.13%) is lower than that of the market as a whole (6.33%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5351%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
